BioFocus DPI Takes Global License for Cresset’s Molecular Field Software
News Mar 24, 2008
BioFocus DPI and Cresset BioMolecular Discovery have announced that BioFocus DPI has up-graded its software license with Cresset to provide global access to the entire range of Cresset’s molecular field software for use in drug discovery.
BioFocus DPI and Cresset have been working together for two years on the design and synthesis of BioFocus DPI’s FieldFocus™ libraries, focused libraries for ion channel drug discovery. The success of these libraries in generating hit series validates Cresset’s approach and its use in the design of novel biologically focused libraries.
The new license also extends BioFocus DPI’s coverage to include its parent company, Galapagos. BioFocus DPI and Galapagos will now have the facility to apply molecular field technology to their projects, whether internal research, library design or drug discovery projects for clients.
Beatrice Leigh, CEO of Cresset, commented ‘We have built a close working relationship with BioFocus DPI over the last two years and have a great respect for each other’s technologies and skills. We are delighted to further cement this relationship with the lease of the entire range of Cresset’s software to BioFocus DPI and its parent company, Galapagos.’
“The FieldFocus libraries we have developed using Cresset’s molecular field software have been particularly successful in identifying novel hit-series for ligand-gated ion channels. We are pleased to continue applying Cresset’s technology to develop new FieldFocus libraries and to further contribute to our clients’ medicinal chemistry projects,” said Chris Newton, Senior Vice President of BioFocus DPI.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE